Daiichi Sankyo submits Enhertu sNDA to Japan’s MHLF for patients with HER2 low or HER2 ultralow metastatic breast cancer: Tokyo Saturday, October 5, 2024, 10:00 Hrs [IST] Daiich ...
AstraZeneca and Daiichi Sankyo's Dato-DXd failed to improve survival in a breast cancer study. Gilead Sciences' Kite will bow ...
AstraZeneca and Daiichi Sankyo announced that their drug Enhertu (trastuzumab deruxtecan) has been granted Priority Review by the US FDA for trea ...
Oncolytics stock soars as the company seeks an accelerated approval pathway for its lead candidate, pelareorep, to treat a ...
AstraZeneca and Daiichi Sankyo's supplemental Biologics License Application (sBLA) for Enhertu (trastuzumab deruxtecan) has ...
The market for B7-H3 inhibitors is expected to grow significantly in the coming years. This is due to the rising investment from leading pharma companies such as GSK, Merck, and others, the increasing ...
WILMINGTON, Del. - AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo's supplemental Biologics License Application (sBLA) for ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been accepted by the U.S ...
WILMINGTON, Del. - AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo's supplemental Biologics License Application (sBLA) for ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been accepted by the U.S. Food and ...
Prices for prescription pharmaceutical drugs have skyrocketed, disproportionately making them harder for people of color to ...
The European Commission (EC) has granted approval for Daiichi Sankyo’s Vanflyta (quizartinib) for newly diagnosed fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) positive acute ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback